ECSP12011786A - Material inviable derivado de probióticos para la prevención y el tratamiento de alergias - Google Patents

Material inviable derivado de probióticos para la prevención y el tratamiento de alergias

Info

Publication number
ECSP12011786A
ECSP12011786A ECSP12011786A ECSP12011786A EC SP12011786 A ECSP12011786 A EC SP12011786A EC SP12011786 A ECSP12011786 A EC SP12011786A EC SP12011786 A ECSP12011786 A EC SP12011786A
Authority
EC
Ecuador
Prior art keywords
composition
allergies
inviable
probiotics
prevention
Prior art date
Application number
Other languages
English (en)
Inventor
Tol Eric A F Van
Udo Herz
Harald Renz
Holger Garn
Machtelt Braaksma
Der Werf Maria Johanna Van
Karin M Overkamp
Original Assignee
Mead Johnson Nutrition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co
Publication of ECSP12011786A publication Critical patent/ECSP12011786A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se revela un procedimiento para la preparación de una composición probiótica no viable que tiene propiedades anti-alérgicas (es decir, previene las alergias y/o es anti-alérgica en un sentido terapéutico), el proceso comprende las etapas de (a) someter LGG a cultivación en un medio de cultivo adecuado utilizando un proceso por lotes, (b) recoger el sobrenadante del cultivo en una fase exponencial tardía de la etapa de cultivo; (c) eliminar el contenido líquido del sobrenadante de cultivo a fin de obtener la composición. También revela una composición que comprende una mezcla proteínica, siendo dicha composición obtenida por el procedimiento anterior, y el uso de los mismos en un producto dietético preferiblemente dirigido a mujeres embarazadas, bebés y niños así como en aplicaciones en alimentos para fines médicos específicos.
ECSP12011786 2009-09-11 2012-04-05 Material inviable derivado de probióticos para la prevención y el tratamiento de alergias ECSP12011786A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09170124A EP2295535A1 (en) 2009-09-11 2009-09-11 Probiotic material

Publications (1)

Publication Number Publication Date
ECSP12011786A true ECSP12011786A (es) 2012-07-31

Family

ID=41561153

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011786 ECSP12011786A (es) 2009-09-11 2012-04-05 Material inviable derivado de probióticos para la prevención y el tratamiento de alergias

Country Status (20)

Country Link
US (1) US20110217402A1 (es)
EP (2) EP2295535A1 (es)
JP (1) JP2013504321A (es)
KR (1) KR20120061836A (es)
CN (1) CN102575224A (es)
AU (1) AU2010293145B2 (es)
BR (1) BR112012005533A2 (es)
CA (1) CA2772593C (es)
EC (1) ECSP12011786A (es)
ES (1) ES2614929T3 (es)
IN (1) IN2012DN00951A (es)
MX (1) MX345077B (es)
MY (1) MY160646A (es)
NZ (1) NZ597818A (es)
PE (1) PE20121557A1 (es)
PL (1) PL2475764T3 (es)
RU (1) RU2012114190A (es)
SG (1) SG178230A1 (es)
TW (1) TWI595090B (es)
WO (1) WO2011031149A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130095189A1 (en) * 2011-10-14 2013-04-18 Zeina Jouni Composition and method of phytonutrients for metabolic programming effects
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US20150305384A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
WO2015177246A2 (en) * 2014-05-20 2015-11-26 Biogaia Ab Neonatal microbiome supplementation
US9730969B2 (en) 2015-11-06 2017-08-15 Mead Johnson Nutrition Company Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
JP7057059B2 (ja) 2016-08-22 2022-04-19 株式会社明治 ラクトバチルス・プランタラムの培養物の製造方法
US20180064739A1 (en) 2016-09-06 2018-03-08 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
US20180103675A1 (en) 2016-10-14 2018-04-19 Mead Johnson Nutrition Company Personalized pediatric nutrition products comprising human milk oligosaccharides
US20180161292A1 (en) 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
US10980269B2 (en) 2016-12-12 2021-04-20 Mead Johnson Nutrition Company Protein hydrolysates and methods of making same
US20180160714A1 (en) 2016-12-12 2018-06-14 Mead Johnson Nutrition Company Nutritional compositions containing butyrate and uses thereof
US20180168215A1 (en) 2016-12-21 2018-06-21 Mead Johnson Nutrition Company Nutritional compositions containing inositol and uses thereof
US20180333426A1 (en) 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
US20180332881A1 (en) 2017-05-17 2018-11-22 Mead Johnson Nutrition Company Preterm infant formula containing butyrate and uses thereof
EP3708188A4 (en) * 2017-11-07 2021-12-01 HuBit genomix, Inc. METHOD FOR INHIBITING THE ACQUISITION OF AN ALLERGIC PREDISPOSITION IN THE INFANT PHASE BY SUPPRESSING IGE CLASS-SPECIFIC IMMUNE-REACTIVITY
US20190208807A1 (en) 2018-01-05 2019-07-11 Mead Johnson Nutrition Company Nutritional compositions containing milk-derived peptides and uses thereof
EP3524051A1 (en) * 2018-02-12 2019-08-14 DuPont Nutrition Biosciences ApS Matricial microencapsulation compositions
JP7828338B2 (ja) * 2020-10-16 2026-03-11 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 乳児又は低年齢の小児用フォーミュラ
CN119040223B (zh) * 2024-11-01 2025-02-28 微康益生菌(苏州)股份有限公司 一种具有抗炎抗敏功效的鼠李糖乳酪杆菌rh22及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
WO1992012711A1 (en) 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
US5374567A (en) 1993-05-20 1994-12-20 The United States Of America As Represented By The Secretary Of The Navy Operational amplifier using bipolar junction transistors in silicon-on-sapphire
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6506389B2 (en) 1995-10-20 2003-01-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek (Tno) Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors
US6051552A (en) * 1996-05-30 2000-04-18 Urex Biotech, Inc. Lactobacillus therapies
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
AU4905300A (en) * 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
AU2001284558B2 (en) 2000-08-08 2007-01-04 Genesis Research And Development Corporation Limited Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
EP1458247B1 (en) * 2001-12-20 2014-01-22 Biolactis Inc. Malleable protein matrix and uses thereof
CA2508712A1 (en) * 2002-12-13 2004-07-01 L'oreal Use of an extract of decaffeinated coffee beans in the preparation of a composition intended to stimulate the sebaceous function of the skin by oral administration
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
WO2004112507A1 (en) * 2003-06-23 2004-12-29 Nestec S.A. Infant or follow-on formula
WO2005112976A2 (en) * 2004-04-20 2005-12-01 The University Of Chicago Probiotic compounds from lactobacillus gg and uses therefor
US20100233312A9 (en) * 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233772A1 (en) * 2005-04-15 2006-10-19 Udo Herz Method for preventing or treating the development of respiratory allergies
WO2008052035A1 (en) * 2006-10-24 2008-05-02 Vanderbilt University Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
CA2682730A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2009137159A2 (en) * 2008-04-17 2009-11-12 Trustees Of Dartmouth College Bioactive molecules produced by probiotic bacteria and methods for isolating and using the same

Also Published As

Publication number Publication date
CA2772593A1 (en) 2011-03-17
BR112012005533A2 (pt) 2016-04-26
PE20121557A1 (es) 2012-11-21
MY160646A (en) 2017-03-15
PL2475764T3 (pl) 2017-06-30
ES2614929T3 (es) 2017-06-02
SG178230A1 (en) 2012-03-29
WO2011031149A1 (en) 2011-03-17
KR20120061836A (ko) 2012-06-13
TW201124529A (en) 2011-07-16
CA2772593C (en) 2018-11-27
EP2295535A1 (en) 2011-03-16
AU2010293145B2 (en) 2016-04-14
JP2013504321A (ja) 2013-02-07
MX2012002716A (es) 2012-04-19
CN102575224A (zh) 2012-07-11
NZ597818A (en) 2014-01-31
AU2010293145A1 (en) 2012-03-08
IN2012DN00951A (es) 2015-04-10
RU2012114190A (ru) 2013-10-20
EP2475764B1 (en) 2016-12-14
MX345077B (es) 2017-01-16
TWI595090B (zh) 2017-08-11
US20110217402A1 (en) 2011-09-08
EP2475764A1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
MY160646A (en) Probiotic derived non-viable material for allergy prevention and treatment
AR090473A1 (es) Material no-viable derivado de probioticos apto para la prevencion y tratamiento de infeccion, composicion
Morris et al. The host response to naturally-derived extracellular matrix biomaterials
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
MX2014009628A (es) Uniones a cdim y sus usos.
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MX2010006610A (es) Conjugados de factor de crecimiento de nervios y usos de los mismos.
BR112016023769A2 (pt) célula hospedeira recombinante para a expressão de proteínas de interesse
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
PH12023550246A1 (en) Modified chikungunya viruses and sindbis viruses and uses thereof
AR106578A1 (es) Composiciones nutricionales para la promoción de la función de barrera intestinal y alivio del dolor visceral
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
Hassan et al. The immune-modulator activity of Pseudomonas aeruginosa extracted protein: Azurin Charming Protein
MX2017008902A (es) Alimento y/o producto nutracéutico de tipo bizcocho y método para obtener el mismo a partir de alimento.
EA201390059A1 (ru) Способ производства продуктов, способных настаиваться для получения напитков
MX2010001049A (es) Post-procesamiento de articulo de acido polilactico.
MX2015007884A (es) Composicion de alimento para animales y proceso para produccion.
TH138555A (th) สารโปรไบโอติก
CO2017003313A2 (es) Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso del mismo en com-posiciones farmacéuticas
Fan et al. EXTRACELLULAR VESICLES RELEASED FROM ENHANCED ADIPOSE TISSUE-DERIVED MESENCHYMAL STROMAL CELLS POLARIZE MACROPHAGES TOWARDS A DISTINCT IMMUNOMODULATORY PROFILE
李凤磊 et al. Microbiota improve immune defense against hepadnavirus infection through promoting hepatic γδT-17 cells
CHU et al. Stem cell transplantation for nonunion: an evaluation of its effect
Donzelli et al. Human Mesenchymal Stem Cells and Endothelial Progenitor Cells exert a neuroprotective effect on rat cortical neurons injured by oxygen and glucose deprivation